A carbose is a reversible inhibitor of the intestinal alpha-glucosidases, the oral administration of which delays absorption of carbohydrates. The aim of this study was to investigate the effect of administration of acarbose on parameters of gly-caemic control, lipid parameters and tolerability in ambulant type 1 diabetic subjects. Materials and Methods: Entry criteria included being: diabetic, age below 30 years and a history of at least one episode of diabetic ketoacidosis insufficiently controlled with diet and insulin. The data of 17 patients (6 men and 11 women, mean age 17.2±3.5 (range 14–26) years, median duration of diabetes 8 (range 1–20) years were valid for statistical analysis. Results: During the run-in period HbA1c levels tended to decrease from 9.5±1.1 to 9±1.7%. After 12 weeks of acarbose treatment, the mean level had decreased further to 7.6±1.6% (P: 0.002). Af-ter discontionuing acarbose, HbA1c levels in-creased to a mean level of 8.8±0.9%. A significant reduction in Fasting Plasma Glucose (FPG) (from 195±62 to 139±73 mg/dL, P<0.01) and 2 hour post prandial glucose (2 hppG) was observed with acarbose (from 231±82 to 159±72 mg/dL, P<0.001). Reduction in total cholesterol (from 159±36 to 146±26 mg/dL, p: 0.09) and triglycerides (from100±22 to 81±23 mg/dL, p: 0.02) was de-tected after treatment with acarbose. No signifi-cant changes were observed in HDL cholesterol. The most frequent reported adverse events were flatulence (7 subjects) and mild abdominal pain (2 subjects). Conclusion: We conclude that acarbose up to 3×100 mg/day can be a valuable adjunct to insu-lin in improving metabolic control in persons with type 1 diabetes

"/> A carbose is a reversible inhibitor of the intestinal alpha-glucosidases, the oral administration of which delays absorption of carbohydrates. The aim of this study was to investigate the effect of administration of acarbose on parameters of gly-caemic control, lipid parameters and tolerability in ambulant type 1 diabetic subjects. Materials and Methods: Entry criteria included being: diabetic, age below 30 years and a history of at least one episode of diabetic ketoacidosis insufficiently controlled with diet and insulin. The data of 17 patients (6 men and 11 women, mean age 17.2±3.5 (range 14–26) years, median duration of diabetes 8 (range 1–20) years were valid for statistical analysis. Results: During the run-in period HbA1c levels tended to decrease from 9.5±1.1 to 9±1.7%. After 12 weeks of acarbose treatment, the mean level had decreased further to 7.6±1.6% (P: 0.002). Af-ter discontionuing acarbose, HbA1c levels in-creased to a mean level of 8.8±0.9%. A significant reduction in Fasting Plasma Glucose (FPG) (from 195±62 to 139±73 mg/dL, P<0.01) and 2 hour post prandial glucose (2 hppG) was observed with acarbose (from 231±82 to 159±72 mg/dL, P<0.001). Reduction in total cholesterol (from 159±36 to 146±26 mg/dL, p: 0.09) and triglycerides (from100±22 to 81±23 mg/dL, p: 0.02) was de-tected after treatment with acarbose. No signifi-cant changes were observed in HDL cholesterol. The most frequent reported adverse events were flatulence (7 subjects) and mild abdominal pain (2 subjects). Conclusion: We conclude that acarbose up to 3×100 mg/day can be a valuable adjunct to insu-lin in improving metabolic control in persons with type 1 diabetes

"/>

Effects of Acarbose in Metabolic Control of Patients with Type 1 Diabetes Mellitus

AUTHORS

F Sharifi 1 , * , M Ghazi Saidi 1 , N Mousavi Nasab 1

1 Metabolic Diseases Research Center, Zanjan

How to Cite: Sharifi F, Ghazi Saidi M, Mousavi Nasab N. Effects of Acarbose in Metabolic Control of Patients with Type 1 Diabetes Mellitus, Int J Endocrinol Metab. Online ahead of Print ; 6(1):13-19.

ARTICLE INFORMATION

International Journal of Endocrinology and Metabolism: 6 (1); 13-19
Article Type: Original Article
Received: October 1, 2007
Accepted: December 27, 2007
READ FULL TEXT

Abstract

A carbose is a reversible inhibitor of the intestinal alpha-glucosidases, the oral administration of which delays absorption of carbohydrates. The aim of this study was to investigate the effect of administration of acarbose on parameters of gly-caemic control, lipid parameters and tolerability in ambulant type 1 diabetic subjects. Materials and Methods: Entry criteria included being: diabetic, age below 30 years and a history of at least one episode of diabetic ketoacidosis insufficiently controlled with diet and insulin. The data of 17 patients (6 men and 11 women, mean age 17.2±3.5 (range 14–26) years, median duration of diabetes 8 (range 1–20) years were valid for statistical analysis. Results: During the run-in period HbA1c levels tended to decrease from 9.5±1.1 to 9±1.7%. After 12 weeks of acarbose treatment, the mean level had decreased further to 7.6±1.6% (P: 0.002). Af-ter discontionuing acarbose, HbA1c levels in-creased to a mean level of 8.8±0.9%. A significant reduction in Fasting Plasma Glucose (FPG) (from 195±62 to 139±73 mg/dL, P<0.01) and 2 hour post prandial glucose (2 hppG) was observed with acarbose (from 231±82 to 159±72 mg/dL, P<0.001). Reduction in total cholesterol (from 159±36 to 146±26 mg/dL, p: 0.09) and triglycerides (from100±22 to 81±23 mg/dL, p: 0.02) was de-tected after treatment with acarbose. No signifi-cant changes were observed in HDL cholesterol. The most frequent reported adverse events were flatulence (7 subjects) and mild abdominal pain (2 subjects). Conclusion: We conclude that acarbose up to 3×100 mg/day can be a valuable adjunct to insu-lin in improving metabolic control in persons with type 1 diabetes

Full Text

Full text is available in PDF

© 0, International Journal of Endocrinology and Metabolism. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
COMMENTS

LEAVE A COMMENT HERE: